Nosha Farhadfar, M.D.
Assistant Professor
Department:
MD-HEMATOLOGY/ONCOLOGY
Business Phone:
(352) 273-7832
Business Email:
nosha.farhadfar@medicine.ufl.edu
About Nosha Farhadfar
Nosha Farhadfar, MD, is a clinical associate professor of medicine in the division of hematology. She received her internal medicine degree from Winthrop University Hospital and went on to complete a fellowship in hematology-oncology at the Winthrop University Hospital, serving as a chief fellow. She then completed a blood and marrow transplant fellowship at the Mayo Clinic in Rochester, MN.
Board certified in internal medicine and oncology, Dr. Farhadfar’s clinical interests include evaluation and management of patients with hematologic malignances, blood and bone marrow transplantation and treatment of graft-versus-host disease.
Dr. Farhadfar’s expertise and research interests focus on management of acute and chronic graft-versus-host disease and late effects of hematopoietic stem cell transplantation.
Professional Memberships: American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, American Society of Bone Marrow Transplantation.
Board Certifications
-
Internal MedicineAmerican Board of Internal Medicine
-
Medical OncologyAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Cancer
- Hematology
- Hematology and Oncology
- Oncology
- Oncology
Areas of Interest
- Bone marrow transplant
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-2752-9604
Publications
2023
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.
American journal of hematology.
98(4):608-619
[DOI] 10.1002/ajh.26834.
[PMID] 36606713.
2023
Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders.
Pediatric blood & cancer.
70(7)
[DOI] 10.1002/pbc.30322.
[PMID] 37046407.
2023
Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors.
Transplantation and cellular therapy.
29(3):202.e1-202.e8
[DOI] 10.1016/j.jtct.2022.11.016.
[PMID] 36427784.
2023
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.
Haematologica.
108(1):150-160
[DOI] 10.3324/haematol.2021.280203.
[PMID] 35443559.
2023
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.
Transplantation and cellular therapy.
29(3):208.e1-208.e6
[DOI] 10.1016/j.jtct.2022.12.017.
[PMID] 36584941.
2022
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation.
Blood advances.
6(3):746-749
[DOI] 10.1182/bloodadvances.2021005208.
[PMID] 34753172.
2022
Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.
Transplantation and cellular therapy.
28(10):712.e1-712.e8
[DOI] 10.1016/j.jtct.2022.07.014.
[PMID] 35863740.
2022
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.
The Lancet. Haematology.
9(9):e660-e669
[DOI] 10.1016/S2352-3026(22)00206-X.
[PMID] 35907408.
2022
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
Blood advances.
6(1):339-357
[DOI] 10.1182/bloodadvances.2021004916.
[PMID] 34547770.
2022
Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
Bone marrow transplantation.
57(7):1150-1163
[DOI] 10.1038/s41409-022-01591-z.
[PMID] 35523848.
2022
Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
Transplantation and cellular therapy.
28(6):335.e1-335.e17
[DOI] 10.1016/j.jtct.2021.10.013.
[PMID] 34757220.
2022
Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
37(12):2466-2471
[DOI] 10.1002/jbmr.4708.
[PMID] 36151778.
2022
Multiple oral squamous cell carcinoma 6 years after allogeneic stem cell transplantation complicated with chronic graft-versus-host disease: A case report.
SAGE open medical case reports.
10
[DOI] 10.1177/2050313X221118203.
[PMID] 36003891.
2022
Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program.
Frontiers in immunology.
13
[DOI] 10.3389/fimmu.2022.937900.
[PMID] 36203566.
2022
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.
Transplantation and cellular therapy.
28(4):187.e1-187.e10
[DOI] 10.1016/j.jtct.2022.01.017.
[PMID] 35081472.
2022
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.
JAMA oncology.
8(3):404-411
[DOI] 10.1001/jamaoncol.2021.6846.
[PMID] 35024768.
2022
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.
Blood advances.
6(3):828-847
[DOI] 10.1182/bloodadvances.2021004881.
[PMID] 34551064.
2022
Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors.
Transplantation and cellular therapy.
28(9):606.e1-606.e8
[DOI] 10.1016/j.jtct.2022.05.035.
[PMID] 35662590.
2022
The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor’s Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials.
Transplantation and cellular therapy.
28(9):603.e1-603.e7
[DOI] 10.1016/j.jtct.2022.05.042.
[PMID] 35688325.
2021
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States
Cancer.
127(1):82-92
[DOI] 10.1002/cncr.33208.
[PMID] 32966625.
2021
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.
Blood advances.
5(18):3528-3539
[DOI] 10.1182/bloodadvances.2021004865.
[PMID] 34496026.
2021
Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden.
Transplantation and cellular therapy.
27(3):264.e1-264.e7
[DOI] 10.1016/j.jtct.2020.11.018.
[PMID] 33781533.
2021
Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States
Cancer.
127(4):609-618
[DOI] 10.1002/cncr.33232.
[PMID] 33085090.
2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
Leukemia.
35(6)
[DOI] 10.1038/s41375-021-01233-1.
[PMID] 33782538.
2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
Leukemia.
35(7)
[DOI] 10.1038/s41375-021-01304-3.
[PMID] 34091601.
2021
Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.
Bone marrow transplantation.
56(9)
[DOI] 10.1038/s41409-021-01353-3.
[PMID] 34017072.
2021
Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis.
Bone marrow transplantation.
56(2)
[DOI] 10.1038/s41409-020-0963-9.
[PMID] 32514157.
2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.
Transplantation and cellular therapy.
27(11):921.e1-921.e10
[DOI] 10.1016/j.jtct.2021.08.007.
[PMID] 34403791.
2021
Gut Microbiota Dysbiosis Associated with Persistent Fatigue in Hematopoietic Cell Transplantation Survivors.
Transplantation and cellular therapy.
27(6):498.e1-498.e8
[DOI] 10.1016/j.jtct.2021.02.017.
[PMID] 33775619.
2021
Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023.
Transplantation and cellular therapy.
27(2):183.e1-183.e7
[DOI] 10.1016/j.bbmt.2020.10.006.
[PMID] 33045387.
2021
Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.
Bone marrow transplantation.
56(9):2108-2117
[DOI] 10.1038/s41409-021-01261-6.
[PMID] 33864019.
2021
Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Transplantation and cellular therapy.
27(5):410-422
[DOI] 10.1016/j.jtct.2021.02.030.
[PMID] 33775617.
2021
Microbiota phylogenic analysis revealed decreased abundance of Faecalibacterium prausnitzii, an anti-inflammatory commensal bacterium, in patients with chronic graft-versus-host disease.
Hematology/oncology and stem cell therapy.
14(3):263-265
[DOI] 10.1016/j.hemonc.2021.03.004.
[PMID] 33785388.
2021
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report.
Transplantation and cellular therapy.
27(7):545-557
[DOI] 10.1016/j.jtct.2021.03.033.
[PMID] 33839317.
2021
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report.
Transplantation and cellular therapy.
27(8):632-641
[DOI] 10.1016/j.jtct.2021.03.029.
[PMID] 33836313.
2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
39(18):1971-1982
[DOI] 10.1200/JCO.20.03502.
[PMID] 33905264.
2021
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
39(17):1865-1877
[DOI] 10.1200/JCO.20.01086.
[PMID] 33449816.
2021
Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis
Cancer Medicine.
10(1):70-78
[DOI] 10.1002/cam4.3568.
[PMID] 33169938.
2021
Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.
Transplantation and cellular therapy.
27(8):679.e1-679.e8
[DOI] 10.1016/j.jtct.2021.04.013.
[PMID] 33895402.
2021
Severity of Acute Graft-versus-Host Disease and Associated Healthcare Resource Utilization, Cost, and Outcomes.
Transplantation and cellular therapy.
27(12):1007.e1-1007.e8
[DOI] 10.1016/j.jtct.2021.09.004.
[PMID] 34537422.
2021
The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic.
Transplantation and cellular therapy.
27(6):507-516
[DOI] 10.1016/j.jtct.2021.03.015.
[PMID] 33865804.
2021
Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature.
Hematology/oncology and stem cell therapy.
14(3):246-251
[DOI] 10.1016/j.hemonc.2019.10.002.
[PMID] 32199933.
2020
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
26(11):2139-2146
[DOI] 10.1016/j.bbmt.2020.08.003.
[PMID] 32781289.
2020
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
Cancer.
126(23):5077-5087
[DOI] 10.1002/cncr.33171.
[PMID] 32965680.
2020
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
JAMA oncology.
6(7):1011-1018
[DOI] 10.1001/jamaoncol.2020.1278.
[PMID] 32496525.
2020
Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell Transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
26(11):2001-2010
[DOI] 10.1016/j.bbmt.2020.07.023.
[PMID] 32717434.
2020
Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients.
Hematology/oncology and stem cell therapy.
13(1):23-31
[DOI] 10.1016/j.hemonc.2019.08.003.
[PMID] 31629722.
2020
Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
26(6):1210-1217
[DOI] 10.1016/j.bbmt.2020.02.011.
[PMID] 32088366.
2020
Dietary Intake and Diet Quality of Hematopoietic Stem Cell Transplantation Survivors.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
26(6):1154-1159
[DOI] 10.1016/j.bbmt.2020.02.017.
[PMID] 32105830.
2020
Global Metabolomics in Allogeneic Hematopoietic Cell Transplantation Recipients Discordant for Chronic Graft-versus-Host Disease.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
26(10):1803-1810
[DOI] 10.1016/j.bbmt.2020.06.014.
[PMID] 32592859.
2020
Graft-versus-host disease of the kidney.
Hematology/oncology and stem cell therapy.
13(3):178-179
[DOI] 10.1016/j.hemonc.2019.01.003.
[PMID] 30807739.
2020
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
Leukemia.
34(12):3338-3347
[DOI] 10.1038/s41375-020-0830-0.
[PMID] 32313109.
2020
Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis.
Bone marrow transplantation.
55(11):2121-2131
[DOI] 10.1038/s41409-020-0911-8.
[PMID] 32355289.
2020
Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.
JAMA network open.
3(1)
[DOI] 10.1001/jamanetworkopen.2019.18668.
[PMID] 31913492.
2020
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.
Blood advances.
4(6):983-992
[DOI] 10.1182/bloodadvances.2019001126.
[PMID] 32168378.
2020
Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation
Cancer.
126(10):2279-2287
[DOI] 10.1002/cncr.32752.
[PMID] 32049359.
2020
Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes.
Current oncology (Toronto, Ont.).
27(6):e596-e606
[DOI] 10.3747/co.27.6327.
[PMID] 33380875.
2020
Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
26(3):553-561
[DOI] 10.1016/j.bbmt.2019.11.003.
[PMID] 31726205.
2020
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.
Blood advances.
4(13):3180-3190
[DOI] 10.1182/bloodadvances.2019001266.
[PMID] 32663298.
2020
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
26(8):1459-1468
[DOI] 10.1016/j.bbmt.2020.05.001.
[PMID] 32434056.
2020
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases.
Blood advances.
4(9):2084-2094
[DOI] 10.1182/bloodadvances.2019000839.
[PMID] 32396620.
2020
The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
26(6):1137-1143
[DOI] 10.1016/j.bbmt.2020.02.006.
[PMID] 32062061.
2020
Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield.
Blood advances.
4(4):706-716
[DOI] 10.1182/bloodadvances.2019000923.
[PMID] 32092138.
2019
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Blood advances.
3(12):1837-1847
[DOI] 10.1182/bloodadvances.2018028316.
[PMID] 31208955.
2019
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
Journal of hematology & oncology.
12(1)
[DOI] 10.1186/s13045-018-0696-z.
[PMID] 30630534.
2019
Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
25(6):1099-1106
[DOI] 10.1016/j.bbmt.2019.02.015.
[PMID] 30794931.
2019
Correction: Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.
Bone marrow transplantation.
54(5):782-783
[DOI] 10.1038/s41409-019-0472-x.
[PMID] 30809032.
2019
Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
25(5):e145-e154
[DOI] 10.1016/j.bbmt.2018.11.033.
[PMID] 30521975.
2019
Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.
Bone marrow transplantation.
54(5):648-661
[DOI] 10.1038/s41409-018-0339-6.
[PMID] 30531955.
2019
Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
25(2):e46-e54
[DOI] 10.1016/j.bbmt.2018.11.021.
[PMID] 30481594.
2019
Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.
Bone marrow transplantation.
54(5):662-673
[DOI] 10.1038/s41409-018-0340-0.
[PMID] 30531954.
2019
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
Blood advances.
3(12):1826-1836
[DOI] 10.1182/bloodadvances.2019000050.
[PMID] 31201170.
2019
The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
25(7):1325-1330
[DOI] 10.1016/j.bbmt.2019.01.034.
[PMID] 30716454.
2018
Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis.
Blood advances.
2(8):933-940
[DOI] 10.1182/bloodadvances.2018018531.
[PMID] 29685953.
2018
Thyroid dysfunction in adult hematopoietic cell transplant survivors: risks and outcomes.
Bone marrow transplantation.
53(8):977-982
[DOI] 10.1038/s41409-018-0109-5.
[PMID] 29410547.
2017
Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
Blood cancer journal.
7(12)
[DOI] 10.1038/s41408-017-0007-x.
[PMID] 29176662.
2016
Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review.
Journal of oncology practice.
12(7):611-21
[DOI] 10.1200/JOP.2016.013268.
[PMID] 27407157.
2016
New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
Leukemia research.
49:13-21
[DOI] 10.1016/j.leukres.2016.07.009.
[PMID] 27521873.
2016
Overview of the progress on haploidentical hematopoietic transplantation.
World journal of transplantation.
6(4):665-674
[DOI] 10.5500/wjt.v6.i4.665.
[PMID] 28058216.
2016
Treatment of Myelofibrosis: A Moving Target.
Cancer journal (Sudbury, Mass.).
22(1):51-61
[DOI] 10.1097/PPO.0000000000000169.
[PMID] 26841017.
2014
Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.
The oncologist.
19(5):459-65
[DOI] 10.1634/theoncologist.2013-0311.
[PMID] 24705979.
Grants
Jun 2022
ACTIVE
A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation to Reduce the Risk of Infection and Graft vs. Host Disease
Role: Principal Investigator
Funding: MEDPACE
via SERES THERAPEUTICS
Sep 2021
ACTIVE
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy
Role: Principal Investigator
Funding: MEDPACE
via SYNDAX PHARMACEUTICALS
Jul 2021
ACTIVE
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
Role: Principal Investigator
Funding: NATL MARROW DONOR PROGRAM
May 2020
– Nov 2022
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF EQ001 IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE GRAFT VERSUS HOST DISEASE
Role: Principal Investigator
Funding: LABCORP DRUG DEVELOPMENT
via EQUILLIUM
Apr 2020
ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Mar 2019
ACTIVE
Abatacept Combined with a Calcinerurin Inhibitor and Methotrexate for Graft versus Host Disease Prophylaxis: A Randomized Controlled Trial
Role: Principal Investigator
Funding: CHILDRENS HOSPITAL CORPORATION
via BRISTOL MYERS SQUIBB CO
Dec 2018
– Nov 2022
Clinical Presentation, Outcome and Economic Burden of Acute Graft versus Host Disease in Allogeneic Stem Cell Transplant Recipients
Role: Principal Investigator
Funding: CSL BEHRING
Sep 2018
– Jul 2021
Developing the Biobehavioral Foundation for Self-Management of Psychoneurological Symptoms in Hematopoietic Cell Transplant (HCT) Survivors
Role: Co-Investigator
Funding: NATL INST OF HLTH NINR
Mar 2018
– Mar 2023
Clinical Presentation, Treatment, and Outcomes of Grade 2-4 Acute Graft Versus Host Disease (GVHD) Patients after Allogeneic Hematopoietic Stem Cell Transplants (HSCT): A Multi-Center Chart Audit Study
Role: Principal Investigator
Funding: CTI CLINICAL TRIAL SERVICES
via INCYTE CORPORATION
Nov 2017
– Nov 2022
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of INCB039110 or Placebo in Combination With Corticosteroids for the Initial Systemic Treatment of Acute Graft-Versus-Host Disease
Role: Principal Investigator
Funding: INCYTE CORPORATION
Sep 2017
– Mar 2023
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogenic stem cell transplantation
Role: Principal Investigator
Funding: INCYTE CORPORATION
Jul 2017
– Jul 2022
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via GILEAD SCIENCES
Jun 2017
– Aug 2022
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Role: Principal Investigator
Funding: INVENTIV HEALTH CLINICAL LLC
via INCYTE CORPORATION
Apr 2017
– Jun 2021
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Aug 2016
– Aug 2021
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
Role: Principal Investigator
Funding: NATL MARROW DONOR PROGRAM
Feb 2015
ACTIVE
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Dec 2012
– Dec 2019
OSTEONECROSIS OF THE JAW (ONJ) CASE REGISTRY
Role: Principal Investigator
Funding: AMGEN INC
Education
Fellowship – Hematology
2016
·
Mayo Clinic
Fellowship – Hematology & Oncology
2015
·
Winthrop University Hospital
Residency – Internal Medicine/Family Practice
2012
·
Winthrop University Hospital
Medical School
2009
·
St. Matthew's University – Grand Cayman
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- nosha.farhadfar@medicine.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610